Featured Research

from universities, journals, and other organizations

Stopping Statins May Cause Rebound That Triples Risk Of Death

Date:
March 6, 2002
Source:
American Heart Association
Summary:
Heart disease patients who discontinued using cholesterol-lowering drugs while they were hospitalized for chest pain had triple the risk of death or heart attack as people who kept taking their medicine, say researchers in the latest rapid access publication of Circulation: Journal of the American Heart Association.

DALLAS (March 4, 2002) -– Heart disease patients who discontinued using cholesterol-lowering drugs while they were hospitalized for chest pain had triple the risk of death or heart attack as people who kept taking their medicine, say researchers in today’s rapid access publication of Circulation: Journal of the American Heart Association.

“The message to physicians is: Don’t stop statins,” says Christian W. Hamm, M.D., one of the study authors. “Withdrawal of statin therapy shortly after the onset of symptoms completely eliminated the protective effect of statins in coronary heart disease patients hospitalized with severe chest pain.”

Hamm is director of cardiology at the Kerckhoff Heart Center in Bad Nauheim, Germany, and professor of medicine and cardiology at the University of Hamburg.

The researchers examined the medical records of 1,616 patients who had previously participated in an international clinical trial called PRISM – Platelet Receptor Inhibition in Ischemic Syndrome Management study. The study compared the effectiveness of two blood-thinning drugs – tirofiban versus heparin – in coronary heart disease patients hospitalized with accelerating heart pain.

When admitted to the hospital, 465 patients had been taking a statin drug for six months. Statin therapy was continued in 379 patients and discontinued in 86. After the 30-day point, researchers examined the rates of death and nonfatal heart attacks. Patients who were kept on their medication had half (.49 times) the risk of death or a nonfatal heart attack of people who had never taken a statin drug. Those who were not continued on the drugs after hospitalization had 2.93 times the risk of those who continued taking statins.

“The increase in deaths and acute heart attacks was only explained by the statin withdrawal,” says Hamm.

Moreover, one week after hospitalization, compared with patients who stayed on their medication, a significantly higher number of patients who were taken off their medication had undergone a procedure to restore blood flow through their coronary arteries.

One hundred and sixty-five patients treated with a statin after being hospitalized had fewer deaths or nonfatal heart attacks than patients who had never taken statins.

Hamm says there is no specific protocol suggesting hospitalized patients discontinue statin drugs, so physicians either assumed that statins were no longer beneficial or they simply forgot to continue it. Statins are a family of drugs known as HMG-CoA reductase inhibitors. They have proven very effective at reducing the risk of death among patients with stable coronary heart disease. However, most previous statin trials excluded patients who had suffered an acute coronary syndrome (heart attack or angina) within the preceding three to six months.

The drugs appear to do more than lower cholesterol. They reduce artery inflammation, the ability of platelets to clump into blood clots, and the proliferation of smooth muscle cells in the arteries – each of which may reduce the risk of a heart attack, says Hamm.

Statins also increase the release of protective nitric oxide from the cells lining the inner walls of heart arteries. Animal research indicated that suddenly withdrawing statins causes a rebound phenomenon. Rather than simply returning to normal, the level of nitric oxide released by cells drops below normal.

“We tried to show that the withdrawal of statins in humans results in a rebound phenomenon and has an adverse impact on patients with acute coronary syndromes,” says Hamm. “A placebo controlled, prospective study appears unethical to test this hypothesis. That is why we preformed this retrospective analysis.”

Three drugs accounted for 94.5 percent of the statins prescribed for the patients: simvastatin, marketed as Zocor (50 percent), lovastatin, known as Mevacor (24.1 percent), and pravastatin, sold as Pravachol (20.4 percent).

“All the statins appeared to provide a similar protective effect when patients were pretreated for at least six months prior to hospitalization,” says Hamm.

“There was no evidence that the discontinuation of the statins was related to the risk profile of the patients,” says Hamm. “Risk factors, including baseline cholesterol levels and troponin T levels at the beginning of the study were similar in patients who remained on statins and those who stopped taking statins after admission.”

Troponin T is a protein released by heart cells damaged because they do not get enough oxygen. Evaluating the protein in the blood of someone with accelerating chest pain provides a good indication of whether the patient is likely to suffer a heart attack in the near future.

Co-authors are Christopher Heeschen, M.D.; Ulrich Laufs, M.D.; Steven Snapinn, Ph.D.; Michael Böhm, M.D.; and Harvey D. White, M.D.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Cite This Page:

American Heart Association. "Stopping Statins May Cause Rebound That Triples Risk Of Death." ScienceDaily. ScienceDaily, 6 March 2002. <www.sciencedaily.com/releases/2002/03/020306074451.htm>.
American Heart Association. (2002, March 6). Stopping Statins May Cause Rebound That Triples Risk Of Death. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2002/03/020306074451.htm
American Heart Association. "Stopping Statins May Cause Rebound That Triples Risk Of Death." ScienceDaily. www.sciencedaily.com/releases/2002/03/020306074451.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins